Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop

TFR (ie, stopping tyrosine kinase inhibitor [TKI] therapy following achievement of sustained deep molecular response [DMR]) is an emerging treatment goal for patients with CML-CP. TFR was first demonstrated in the Stop Imatinib (STIM) trial ( ≈40% of patients maintained DMR 1 year after stopping long-term imatinib), and trials investigating TFR following second-generation TKIs are ongoing. The ENEST TFR trial program is specifically evaluating TFR following nilotinib treatment; primary results from ENESTfreedom (TFR after frontline nil otinib) and ENESTop (TFR after second-line nilotinib) were recently presented.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research